U.K. artificial intelligence company Sensyne Health is linking arms with real-world data network OMNY Health to double the number of patients in its database.
Sensyne will tap into OMNY's 22 million patient records to support data analytics and clinical research, the companies said Friday.
OMNY will give Sensyne access to its records, which hide patients' identities, across multiple therapeutic areas. The partners will also combine forces on commercial projects for "ethical medical research."
Sensyne already has 22.1 million patient records in its global medical research data set through strategic partners in the U.S. and the U.K. OMNY's network includes 50,000 providers in 40 states.
RELATED: Sensyne launches real-world patient data platform, joining growing call for such data
The new patient data set will allow Sensyne to help biopharma clients with synthetic control arms, identifying and selecting patients for trials, late-phase clinical trial designs, pricing decisions and commercialization efforts.
Sensyne revealed its data analytics platform last month through research partners at U.S. health systems and the U.K.'s National Health Service.